<DOC>
	<DOCNO>NCT02138786</DOCNO>
	<brief_summary>This multi-center , Phase 2 , single arm , open-label study oral selinexor monotherapy patient patient Richter 's transformation , arise set prior CLL , least one chemo-immunotherapy regimen CLL .</brief_summary>
	<brief_title>Selinexor Initial Relapsed/Refractory Richter 's Transformation</brief_title>
	<detailed_description>Multi-center , Phase 2 , single arm , open-label study oral selinexor monotherapy patient Richter 's transformation , arise set prior CLL , document histologically confirm lymphoma , include diffuse large B-cell ( DLBCL ) immunoblastic variant . Eligible patient must least one prior regimen CLL . Approximately 50 patient anticipate treated study . Eligible patient follow screen receive selinexor orally twice weekly ( e.g. , Monday Wednesday Tuesday Thursday ) dose 60 mg . The selinexor dose may increase 80 mg Cycle 1 unless clinically contraindicate . Patients may continue multiple treatment cycle give dose ; maximum treatment duration . Each cycle 28 day . Dose adjustment make appropriate investigator .</detailed_description>
	<criteria>Richter 's transformation , arise set prior CLL , document histologically confirm lymphoma , include large Bcell immunoblastic variant . All patient must receive least one prior regimen CLL , include cytotoxic chemotherapy , antiCD20 monoclonal antibody , BTK inhibitor , PI3K inhibitor . Patients may receive high dose chemotherapy/autologous stem cell transplant ( HDT/ASCT ) allogeneic hematopoietic stem cell transplant ( allo SCT ) . One measurable ( &gt; 1.5 cm long dimension ) disease sit CT ( preferably PET/CT ) , CT contraindicate , MRI ( preferably PET/MRI ) scan . Objective document evidence disease progression study entry ECOG status ≤ 2 Radiation , chemotherapy , immunotherapy anticancer therapy ≤ 2 week prior Cycle 1 Day 1 , except ibrutinib may continue one day prior initiation selinexor ; radioimmunotherapy 4 week prior Cycle 1 Day 1 . Patients must recover Grade ≤ 1 clinically significant adverse effect . Prolymphocytic transformation Less 1 month since completion autologous stem cell transplantation le 3 month since completion allogeneic stem cell transplantation Major surgery within 4 week C1D1 Impairment GI function GI disease could interfere absorption selinexor , include obstruct GI tract uncontrolled vomit diarrhea . Inability unwillingness take supportive medication include centrally act appetite stimulant ( e.g. , mirtazapine olanzapine ) peripherally act appetite stimulant ( e.g. , low dose glucocorticoid megesterol acetate ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Richter 's Transformation</keyword>
	<keyword>Richter 's Syndrome</keyword>
	<keyword>Karyopharm</keyword>
	<keyword>selinexor</keyword>
	<keyword>KPT-330</keyword>
	<keyword>SIRRT</keyword>
	<keyword>CLL</keyword>
</DOC>